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Objective To determine both the prevalence of group I b-lactamase-related resistance and the clinical
setting inwhich resistance to expanded-spectrum cephalosporins occurs.
Methods Isolates of Enterobacter spp. were sensitivity tested to a range of antibiotics, and selected isolates
were DNA¢ngerprinted by pulsed-¢eld gel electrophoresis.Themedical records of all patients with
positive cultures for Enterobacter spp. were reviewed to determine the e¡ect of previous antibiotic treatment
on the susceptibility pro¢le of these organisms.
Results The crude incidence of colonization/infection (n 315) was 0.51per100 patients and 0.73 per
1000 days of hospitalization.The 4 -day and 7-day Kaplan^Meier rates of colonization/infectionwith
Enterobacterwere estimated to be 7.57% (standard deviation (SD 3.26%) and 4.16% (SD 2.88%)),
respectively.The time lag to colonization/infectionwith isolates producing large amounts of Bush group1
b-lactamase (HLBL) (27.35 þ 27.30 days) was signi¢cantlydi¡erent from that to colonization/infectionwith
wild-type isolates (13.59 þ 17.93 days) (P 0.036). Ninety-six isolates (30.5%) demonstrated acquired
resistance to expanded-spectrum cephalosporins: 34 isolates (10.8%) produced extended-spectrum b-
lactamase, and 62 isolates (19.7%) produced HLBL.The 89 Enterobacter isolates susceptible to third-
generation cephalosporins yielded 84major DNApatterns, and the 45HLBL isolates yielded 38major
DNApatterns.The risk of colonization/infectionwithHLBL-producing Enterobacterwas higher in cases of
antimicrobial treatment with third-generation cephalosporins or a £uoroquinolone, and in cases of urinary
tract colonization/infection.
Conclusions The judicious use in hospitals of both expanded-spectrum cephalosporins and other
antibiotics such as £uoroquinolones is necessary to curtail the emergence of resistance in Enterobacter spp.
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I N T R O D U C T I O N
Enterobacter spp. are pathogenic and their incidence as causative
agents of infection has increased in recent years [1], particu-
larly in hospital-acquired infections. This is particularly true
for E. cloacae and E. aerogenes, which together account for more
than 90% of clinical isolates of Enterobacter [2,3]. Risk factors
for nosocomial Enterobacter infection include the prior use of
antimicrobial agents, prolonged hospital stay, serious underly-
ing illness, immunosuppression, and catheterization [4].
Recently, resistance to expanded-spectrum cephalosporins
(ESCs) and broad-spectrum penicillins (BSPs) has emerged in
Enterobacter spp. It is usually mediated by the high-level pro-
duction of the chromosome-encoded Bush group 1 b-lacta-
mase [5,6] (high-level-expressing b-lactamase (HLBL)) or the
acquisition of plasmids encoding Bush group 2be b-lacta-
mases or extended-spectrum b-lactamases (ESBLs), such as
have been recovered from patients in France [7^9], the USA
[10], and the UK [11]. Strains of Enterobacter associated with
nosocomial infections are often also resistant to other clini-
cally relevant antibiotics such as aminoglycosides, quinolones,
chloramphenicol and imipenem [8,9,11,12].
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The emergence and spread of resistance in nosocomial
pathogens can be limited by improving patient management
procedures, isolating carriers and infected patients (which pre-
vents cross-contamination) and implementing antibiotic poli-
cies aimed at reducing the selection of resistant mutants
during treatment. Molecular approaches have been used to
identify strains beyond the species level in many studies on the
hospital epidemiology of members of the Enterobacteriaceae,
including Enterobacter and Klebsiella species [7,8,10^20]. Clones
within each species must be de¢ned at the molecular level to
enable us to interpret correctly the dynamics of the emergence
and, dissemination of resistant clones [21]. However, the rela-
tionship between the colonization or infection of patients
with antibiotic-resistant bacteria and speci¢c risk factors,
including exposure to broad-spectrum antibiotics, must also
be analyzed.This should make it possible to design and imple-
ment appropriate measures to reduce the level of resistance of
bacteria causing nosocomial infections [2,22].
In June 1995, we began prospective multicenter surveillance
of resistant Enterobacter isolates frompatients at various types of
hospital in the Franche-Comte¨ region of France.We aimed to
determine both the prevalence of group I b-lactamase-related
resistance in our institutions and the clinical setting in which
resistance to ESCs occurs.We report herein the epidemiologic
and microbiological characterization of the isolates obtained
during1995^98.
M A T E R I A L S A N D M E T H O D S
Study location and design
Clinical cultures from all patients admitted to six hospitals in
the Franche-Comte¨ region in eastern France (one teaching
hospital with 1319 beds, four community hospitals, each with
299^665 beds, and one mid-term facility with 120 beds) were
examined to identify possible cases of Enterobacter coloniza-
tion/infection in a non-sequential study (six 1-month peri-
ods: November 1995, period A; May 1996, period B;
November 1996, period C; May 1997, period D; November
1997, period E; and May 1998, period F). Isolates of di¡erent
species of Enterobacterwere DNA¢ngerprinted by pulsed-¢eld
gel electrophoresis and their antibiotic susceptibility pheno-
types determined. The medical records of patients with posi-
tive cultures were also reviewed to assess the relationship of
previous antibiotic treatment to the susceptibility pro¢les of
these organisms.
Bacterial strains
The strains of Enterobacter studied were isolated from various
pathology samples sent to the laboratories of participating
hospitals in Franche-Comte¨ during the six 1-month periods.
All strains isolated from rectal swabs used to screen for fecal
carriers were excluded from the study. All non-duplicate
Enterobacter strains responsible for infection or colonization
were eligible for inclusion irrespective of the site of isolation.
The second and subsequent isolates of the same species
obtained from the same site in the same patient during any 1-
month period were de¢ned as duplicate isolates, regardless of
the time between isolations, and removed from the analysis.
Bacteriologic methods
Enterobacter was identi¢ed using API 20E (BioMe¨rieux, Lyon,
France). A standardized disk di¡usion method [23] with
Mueller^Hinton agar was used to determine susceptibility to
amoxycillin and amoxycillin^clavulanate, extended-spec-
trum penicillins (ticarcillin, ticarcillin^clavulanate, piperacil-
lin and piperacillin^tazobactam), third-generation
cephalosporins (cefotaxime, ceftazidime), imipenem, aztreo-
nam and four other antibiotics, gentamicin, tobramycin, ami-
kacin and cipro£oxacin. The isolates were classed as
susceptible, intermediately resistant or resistant according to
the interpretation criteria recommended by the Comite¨ Fran-
c,ais de l'Antibiogramme (CFA) [23]. Probable ESBL-produ-
cing isolates were detected by the synergistic e¡ects of
amoxycillin^clavulanic acid with cefotaxime, ceftazidime,
aztreonam, and cefepime [17]. Synergy was detected as pre-
viouslydescribed [24]. Other isolates resistant to third-genera-
tion cephalosporins but with no reduction in susceptibility to
cefepimewere classed as probable HLBL-producing isolates. It
should be noted that some HLBL-producing isolates with
ESBL activity may not have been identi¢ed as HLBL-produ-
cing.
DNA ®ngerprinting
One hundred and thirty-four randomized isolates were DNA
¢ngerprinted. Pulsed-¢eld gel electrophoresis of genomic
DNA digested with XbaI was performed as described by
Haertl et al [25], using a clamped homogeneous electric ¢eld
apparatus (CHEF DRIII, Bio-Rad, Hercules, CA, USA). Sta-
phylococcus aureus NCTC 8325 DNA digested with SmaI was
used as amolecular size marker.
Analysis of DNA similarity
Gels were photographed and electrophoretic restriction pat-
terns were analyzed by scanning the photographic negatives.
GelCompar software was used for cluster analysis (Applied
Maths, Kortrijk, Belgium). Each strain was ¢rst compared
with all other strains to calculate similarity using the Dice cor-
relation coe¤cient. The strains were then grouped and the
groups plotted on a dendrogram using the UPGMA clustering
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algorithm (unweighted pair-group method using arithmetic
averages). Major restriction patterns were de¢ned as those dif-
fering bymore than three fragments, andwith similarity coef-
¢cients of <85% as previously described [26,27]. Major
genotypes were designated by numbers, with each variant
indicated by a su¤x letter.We described as `unique patterns'
the patterns including isolates from only one patient, and as
e`pidemic patterns' those including isolates from more than
two patients.
Infection control measures
In mid-1992, the infection control committee at Besanc,on
University Hospital made the control of multiresistant patho-
gens amajor goal. Acontrol programwas progressively imple-
mented, ¢rst in high-risk departments and then, in 1995,
throughout the hospital. Since1995 this program has also been
progressively implemented in community hospitals and mid-
term care facilities in Franche-Comte¨ as part of the `Franc-
Comtois' Network for the Control of Nosocomial Infection.
If a clinical specimen tested positive for multiresistant Gram-
negative bacteria, fecal specimens were obtained from all the
patients in the same unit as the a¡ected patient and screened
for evidence of colonization. Patients testing positive were
kept in separate rooms or grouped together, and special barrier
precautions were implemented, including the use of disposa-
ble gowns and gloves, handwashing with antiseptic soap, and
strict environmental hygienemeasures.
Data collection and baseline data
All patients with a specimen testing positive for Enterobacter
were included. Data collectionwas coordinated by a physician
from the Hygiene and Nosocomial Infection Unit of Besan-
c,on Hospital, who retrospectively completed a standardized
form for each included patient. These forms recorded demo-
graphic characteristics (age, sex), conditions of hospitalization
(previous hospital admissions, length of stay in hospital) and
details of antibiotic treatment (in the 7 days preceding strain
isolation). Prior antibiotic treatment was ¢rst analyzed as a
whole and then according to the individual products used.
The questions asked were worded as follows. Prior antibiotic?
Y/N. If yes, potent anti-Enterobacter antibiotic? If yes, mono-
therapy or combination? ESCs? BSPs? Fluoroquinolone? (Or
other antibiotic?) The data collected also concerned features of
the hospital: the number of beds, nature of the units, and
number of admissions. Fluoroquinolone treatment was classi-
¢ed as ¢rst line or second line (when following therapeutic
failure of the ¢rst line) and expressed as de¢ned daily dose
received before isolation of the Enterobacter strain.
De®nitions
Clinical Enterobacter isolates were classi¢ed as community-
acquired if the sample cultured was obtained within 24 h of
admission from patients who had not been hospitalized dur-
ing the previous 48 h. We classi¢ed colonization/infection
into e`arly'- and `late'-onset groups, using day 4 as the cut-o¡
point. Any clinical features were recorded to enable us to dif-
ferentiate between colonization and infection. Antibiotics
were de¢ned as potent if Enterobacter with the wild-type sus-
ceptibility phenotype was found to be susceptible. BSPs (in
this study exclusively ureidopenicillins þ b-lactamase inhibi-
tor), ESCs, imipenem, aminoglycosides, and £uoroquino-
lones (in this study exclusively cipro£oxacin) were de¢ned as
`potent'anti-Enterobacter antibiotics. Aminopenicillins þ b-lac-
tamase inhibitor, glycopeptides and other anti-Gram-positive
antibiotics were de¢ned as non-potent or less potent anti-
Enterobacter antibiotics.
Statistical analysis
Incidence and occurrence of Enterobacter colonization/
infection
The principal endpoint was determination of the incidence
of enterobacter colonization/infection and the second end-
point was the identi¢cation of risk factors for colonization/
infectionwith HLBL-producing Enterobacter. Crude incidence
was estimated as the total number of cases of Enterobacter colo-
nization/infection divided by the total number of patients
exposed. Time-failure methods were also used, taking into
account the various lengths of exposure in the hospital. These
methods were used to calculate the hazard function, which
estimates the instantaneous risk of becoming colonized/
infected within two given time intervals, 4 and 7 days. The
time at which colonization/infection occurred was calculated
from the date of hospital admission, within a maximum
observation time in the hospital of 120 days. These estimates
were based on the Kaplan^Meier method [28] and actuarial
life table methods [29]. Predictive values were assessed by log-
rank tests at the 5% signi¢cance level [30]. The time required
for colonization/infection was compared for strains with
wild-type susceptibility phenotypes and strains resistant to
ESCs.
Risk factors for colonization/infection with HLBL
Enterobacter
A multivariate cohort analysis was carried out to identify risk
factors for colonization/infection with HLBL-producing
Enterobacter and with susceptible Enterobacter.The variables stu-
died as risk factorswere: sex, age> 60 years, previous hospita-
lization, hospitalization in an intensive care unit, duration of
hospitalization before colonization/infectionwith Enterobacter,
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antibiotic treatment before colonization, and the administra-
tion of antibiotics before colonization. Univariate logistic
regression was used to identify risk factors. Odds ratios were
estimated by exponentiation of regression coe¤cients and cal-
culation of 95% con¢dence intervals (CIs).The chi-square test
was used to test the correlation between variables.Values of P
below 0.05 were considered to be signi¢cant. To adjust for
confounding factors, variables with P-values below 0.1 in uni-
variate analyses were entered into multiple regression models.
Statistical analysis was carried out using BMDP, a statistical
software package produced by theUniversity of California.
R E S U L T S
Incidence of Enterobacter colonization/infection
During the study periods, 61725 patients were admitted to
the various hospitals for a total of 429 070 days. Colonization
or infection with Enterobacter occurred in 272 of the 61725
patients, giving a crude incidence of 0.44%. Forty-three of the
272 patients had two sites of colonization/infection, giving a
crude incidence of 0.51 colonizations/infections (n 315) per
100 patients and of 0.73 per 1000 days of hospitalization.There
was a large di¡erence between the incidence at the University
Hospital and that at other hospitals (Table1). According to the
period and the hospital, crude incidence was between 0.27
(November 1997) and 0.61 per 100 patients (November 1996),
with crude incidence for all other periods between 0.41 and
0.48 per190 patients.
Occurrence of colonization/infection
The instantaneous risk of colonization/infection with Entero-
bacterwas estimated to be 0.0870 in the ¢rst week, 0.0659 in the
second week, and 0.0377 in the third week. The 4 -day and 7-
dayKaplan^Meier rates of colonization/infectionwith Entero-
bacter were estimated to be 7.57% (standard deviation, SD
3.26%) and 4.16% (SD 2.88%), respectively.The time lag to
colonization/infection with HLBL-producing isolates (27.35
þ 27.30 days) was signi¢cantly di¡erent from that with wild-
type isolates (13.59 þ 17.93 days) (P 0.036) and di¡erent from
that for colonization with ESBL-producing isolates (13.00 þ
16.26 days).
Frequency of resistance
Of the 315 Enterobacter isolates, 213 (67.6%) were E. cloacae, 81
(25.7%) were E. aerogenes, and 21 (6.7%) were other species: E.
sakazakii (n14), E. amnigenus (n 5), and E. agglomerans (n
2).The frequency of acquired resistance to ESCs was 30.5% (n
 96): 10.8% of the isolates produced ESBL (n 34) and
19.7%HLBL (n 62) (Figure 1). All ESBL-producing isolates
were E. aerogenes, whereas HLBL-producing isolates were E.
cloacae (n 41; 19.2% of E. cloacae isolates), E. aerogenes (n17;
21% of E. aerogenes isolates) and other Enterobacter species (n
4; 19.0% of other Enterobacter isolates). Table 2 shows the sus-
ceptibility and resistance of the 315 isolates to ESCs, according
to site and ward.The frequency of resistance was signi¢cantly
di¡erent in E. cloacae and other Enterobacter spp. (17.2%) from
Table 1 Incidence of colonization/infection according to the size
and type of hospital
per 100 patientsa per 1000 daysb
Mean Range Mean Range
Teaching hospital
(> 1000 beds)
0.56 0.24±0.89 0.86 0.38±1.30
Community hospital
(< 1000 beds)
0.33 0.11±0.64 0.47 0.11±0.81
aP  0.00002; RR (95% CI)  1.71 (1.33±2.19). bP  <10ÿ5; RR (95%
CI)  1.85 (1.44±2.37).
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Figure 1 Incidence of colonization/infection with Enterobacter
isolates of various antibiotic susceptibility phenotypes in (A)
six hospitals and in (B) BesancËon University Hospital.
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that in E. aerogenes (63%) (P<10ÿ5 and RR 0.31 (0.22^
0.42)). In Besanc,on University Hospital, implementation of a
program for the control of multiresistant pathogens led to a
remarkable drop in the number of ESBL-producing isolates,
whereas the number of HLBL-producing isolates remained
constant throughout the study period (Figure 1). The fre-
quencyof co-resistancewas signi¢cantly higher in ESBL-pro-
ducing isolates than in HLBL-producing isolates for
cipro£oxacin (P<10ÿ5 and RR 4.30 (2.70^6.84)), tobra-
micin (P<10ÿ5 and RR10.03 (4.68^21.50)), and amikacin
(P<10ÿ5 and RR15.80 (5.16^48.41)). It was also higher in
HLBL-producing than in wild-type isolates for cipro£oxacin
(P<10ÿ5 and RR12.36 (4.22^36.22)), gentamicin (P
0.048), tobramicin (P<10ÿ4), and amikacin (P 0.010).
Molecular epidemiology
The 134 isolates from 134 randomized patients comprised 107
E. cloacae isolates and 27 E. aerogenes isolates. The 107 E. cloacae
isolates yielded 96 major DNA patterns: 70 patterns for the 75
wild-type isolates typed (65 (86.6%) unique pattern isolates
and three (4.0%) epidemic pattern isolates) and 27 patterns for
the 32 HLBL-producing isolates typed (24 (75.0%) unique
pattern isolates and three (9.4%) epidemic pattern isolates).
The frequencies of unique pattern isolates and of epidemic
pattern isolates did not di¡er signi¢cantly between wild-type
and HLBL phenotypes (RR and 95% CIs were 1.13 and 0.86^
1.50 for wild-type and 0.23 and 0.05^1.03 forHLBL).One pat-
ternwas found in isolates with di¡erent antibiotic phenotypes,
so the total number of major DNA patterns was 96.Two epi-
demic patterns were identi¢ed, each corresponding to three
isolates: three wild-type isolates for one pattern and three
HLBL-producing isolates for the other.The 27 E. aerogenes iso-
lates yielded 25 major DNApatterns: 14 patterns among the 14
wild-type isolates typed (14 unique pattern isolates and no
epidemic pattern isolates) and11patterns among the13 HLBL-
producing isolates typed (nine (69.2%) unique pattern isolates
and no epidemic pattern isolates). The frequency of unique
pattern isolates did not di¡er signi¢cantly between wild-type
phenotype and HLBL phenotypes (RR and 95% CIs of 1.25
and 0.92^1.70).
Clinical epidemiology
In total, 123 randomized patients were included in the cohort
analysis.The characteristics of the patient population included
are given inTable 3.The variables signi¢cantly associated with
HLBL-producing Enterobacter colonization in both univariate
and multivariate analyses are listed inTable 4.The risk of colo-
nization/infection with HLBL-producing Enterobacter was
higher if the patient was treated with third-generation cepha-
losporins or £uoroquinolone and in cases of urinary coloniza-
tion/infection.The characteristics of the isolates from patients
treated with £uoroquinolones are given in Table 5. Of the
patients treated with ESCs, only one, colonized with an
HLBL-producing isolate, was treated with a combination of
drugs (ESC^aminoglycoside). All patients treated with ESCs
were colonizedwith unique pattern isolates.
D I S C U S S I O N
This study, like others, shows that Enterobacter are able to colo-
nize/infect a large number of hospitalized patients at a wide
variety of sites, including the bloodstream [1,2]. Patients in
Table 2 Susceptibility and resistance of 315 Enterobacter isolates to expanded-spectrum cephalosporins, according to site and ward of isola-
tion
Number of isolates (%)
Wild-type isolates
Extended-spectrum
b-lactamase isolates
High-level-expressing
b-lactamase isolates
Site of isolation
Urine 73 (62.9) 16 (13.8) 27 (23.3)
Respiratory tract 24 (68.4) 5 (14.6) 6 (17.0)
Blood 15 (79.0) 2 (10.5) 2 (10.5)
Other 107 (73.8) 11 (7.6) 27 (18.6)
Ward of isolation
Medical 84 (70.6) 13 (10.9) 22 (18.5)
Surgical 74 (80.4) 3 (3.3) 15 (16.3)
Intensive care 23 (45.1) 12 (23.5) 16 (31.4)
Other 38 (71.7) 6 (11.3) 9 (17.0)
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teaching hospitals, in which major risk factors for Enterobacter
infection (serious underlying illness and immunosuppression)
[4] are encountered, were exposed to the greatest risk.
A prolonged hospital stay is a known risk factor for hospi-
tal-acquired Enterobacter infection [4]. However, more than
25% of the colonizations/infections in this study were com-
munity-acquired, consistent with the results of John et al [31].
In addition, instantaneous risk and the Kaplan^Meier esti-
mates suggested that the rate of colonization/infection with
Enterobacter decreased with the length of hospital exposure. A
signi¢cantly longer period of time was required for coloniza-
tion/infectionwithHLBL-producing isolates than for coloni-
zation/infection with wild-type isolates, as previously
demonstrated [2,32,33]. In this study, more than 16% of iso-
lates were from patients in intensive care units. Such units
accounted for less than 5% of the beds.This suggests that data
Table 3 Main characteristics of the 123 randomized patients included
Wild-type isolates
n 97
High-level-expressing
b-lactamase isolates
n26
Age (years) 57.12  25.24 53.31  29.74
Men 51 (52.6%) 10 (38.5%)
Hospitalization
In intensive care unit 14 (14.4%) 6 (23.1%)
Duration of hospitalization before
colonization/infection (days)
13.59  17.93 27.35  27.30
Total length of stay in the
hospital (days)
28.29  41.60 44.50  36.93
Urinary tract colonization 27 (27.8%) 13 (50.0%)
Hospital acquisition 68 (70.1%) 22 (84.6%)
`Late' onseta 58 (59.8%) 21 (80.8%)
Prior administration of antibiotics
Before colonization 40 (41.2%) 13 (50.0%)
Potent antibiotics 14 (14.4%) 8 (30.8%)
Monotherapy 10 (10.3%) 6 (23.1%)
Expanded-spectrum cephalosporins 1 (1.0%) 4 (15.4%)
Fluoroquinolones 4 (4.1%) 4 (15.4%)
Broad-spectrum penicillins 5 (5.2%) 1 (3.8%)
Imipenem 3 (3.1%) 0 (0.0%)
Aminoglycosides 5 (5.2%) 1 (3.8%)
aColonization/infection classi®ed into `late' onset group using day 4 as a cut-o point.
Table 4 Univariate and multivariate analyses of risk factors for colonization/infection with high-level-expressing b-lactamase Enterobacter
Univariate analysis Multivariate analysis
Risk factor Odds ratio 95% CI Odds ratio 95% CI
Urinary tract colonization 1.80 1.09±2.96 3.12 1.15±8.43
`Late' onseta 1.35 1.05±1.73 NS ±
Prior administration of antibiotics
Potent antibiotics 2.13 1.00±4.53 NS ±
Monotherapy 2.24 0.90±5.59 NS ±
Expanded-spectrum
cephalosporins
14.92 1.74±127.88 28.9 2.79±300
Fluoroquinolones 3.73 1.00±13.92 6.52 1.36±31.2
aColonization/infection classi®ed into `late'-onset group using day 4 as cut-o point. NS, not signi®cant.
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from intensive care units should be analyzed separately from
other hospital data to assess the increasing importance of this
genus as a nosocomial pathogen [4]: the relative risk of becom-
ing colonized/infected with this genus is 13.8 times higher in
intensive care units than in other units.We identi¢ed no sin-
gle-source outbreaks by molecular epidemiology, but the pre-
valence of HLBL-producing isolates was high: mean of 20%
and more than 23% in the University Hospital, as reported in
other surveys [31,34^37]. The rate reported depended on the
site of isolation and the study: higher rates were reported for
urinary tract isolates in this study and in the studies of the
NNIS system [36] and Jacobson et al [22] and for respiratory
tract isolates [32,38^40].
The implementation of a control program based on isola-
tion precautions at Besanc,on Hospital and at the ¢ve other
hospitals resulted in a dramatic decrease in the number of
ESBL-producing isolates in the region, with no decrease in
the number of HLBL-producing isolates. HLBL-producing
isolates were typed to determine the prevalence of cross-con-
tamination.More than 70% of the isolates were clonally unre-
lated.This indicates that, in most cases, colonization was from
an endogenous reservoir. Superinfection was ruled out by
Jacobson et al [22], so the emergence of resistance must indeed
result from the development of resistance in susceptible organ-
isms. Mutants with high-level resistance to third-generation
cephalosporins are generally present at low rates (1 in
10ÿ6ÿ10ÿ7) in the gut £ora of patients, and selection during
therapy allows subsequent overgrowth of these resistant
mutants. This would result in the isolation of HLBL-produ-
cing isolates later in the hospital stay.
Prior treatment with ESCs was associatedwith the isolation
of organisms resistant to these drugs. Many studies have been
published on the emergence of organisms resistant to multiple
b-lactam antibiotics during treatment with ESCs
[2,32,33,38,40^42] and on the role played by limiting the pre-
scription of ESCs [36,43,44]. Jacobson et al demonstrated that
the ESC ceftazidime puts patients at high risk of colonization
by isolates resistant to ESCs [22]. In this study, we also found
that prior exposure to a £uoroquinolone was associated with
the isolation of organisms resistant to ESCs. This is the ¢rst
large, prospective, controlled study to associate £uoroquino-
lone treatment with the isolation of organisms resistant to
ESCs. Nevertheless, it is di¤cult to attach clinical importance
to these e¡ects, because: the sample sizes were small, which is
re£ected in the broadness of the con¢dence intervals (Table 5),
and two HLBL-producing isolates from patients treated with
£uoroquinolone were resistant to these ESCs. Thus, further
studies are required to con¢rm and further explore these
results. However, these results are similar to those of Antania-
dou et al [45], who showed that an 80% reduction in quino-
lone use was associated with a decrease in the frequency of
resistance in various Gram-negative bacilli (P< 0.001). In
another recent study,White et al showed that the introduction
of a restrictive antibiotic policy including cipro£oxacin and
other major antibiotics was followed by a signi¢cant decrease
in resistance to key antibiotics inmany Enterobacteriaceae [46].
Many reports have documented the failure of combination
therapy to prevent the emergence of multiple resistance to
ESCs [2,39,47^49]. In this study, logistic regression analysis
showed no signi¢cant decrease in the development of resis-
tance if combinations were used. In contrast, Jacobson et al
concluded that combination therapy including an aminogly-
coside may decrease the risk of resistance emerging, but that
this measure alone is not su¤cient [22].
Cross-infection is a major barrier to the control of resis-
tance, but the judicious use in hospitals of ESCs and probably
of othermajor antibiotics such as £uoroquinolones is necessary
Table 5 Characteristics of Enterobacter isolates and prescription data from patients treated with ¯uoroquinolone (cipro¯oxacin)
Prescription data Susceptibility to
No. Line Monotherapy DDD b-Lactam antibiotics Cipro¯oxacin DNA pattern
1 Second Yes 13 Wild type R UP
2 First No 3 HLBL S UP
3 First No 3 Wild type S UP
4 First No 12 HLBL S UP
5 First Yes 3 HLBL R UP
6 First No 1 Wild type S UP
7 First No 2 Wild type S UP
8 First No 1 HLBL R UP
DDD, de®ned daily doses; HLBL, high-level-expressing b-lactamase isolates; UP, unique pattern.
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to curtail the emergence and reduce the prevalence of resis-
tance in Enterobacter spp.
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